| Patient | Clara Barton |
|---|---|
| Date of birth | 1973-12-25 |
| Identifiers | MRN HR-NI024-SYN; SSN (made up) 000-24-3357 |
| Document date | 2026-03-03 |
| Author | Eleanor Whitcombe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week depression treatment review. [S]
Ms. Barton returns six weeks after starting sertraline 50 mg. She has had four sessions of cognitive behavioral therapy and has kept a daily plan of small tasks and walks. She went back to work three weeks ago on a 25-hour week and has kept to it. Her mood is a little better on most days and she can concentrate on one report at a time, but she still feels flat, tires by mid-afternoon, and sleeps about five and a half hours. She has had no side effects since the first week and has missed no doses. She has had no suicidal thoughts. She has seen two friends each week. [S]
| Element | Detail |
|---|---|
| Interval change | Somewhat better mood and concentration; still flat and tired |
| Psychotherapy | Four CBT sessions; daily activity plan |
| Work | Back three weeks on a 25-hour week |
| Sleep | About five and a half hours |
| Safety | No suicidal thoughts |
| PHQ-9 | 12, down from 18 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by mid-afternoon; appetite improving; weight up 0.6 kg |
| Gastrointestinal | Negative | No nausea, diarrhea, or bleeding |
| Psychiatric | Positive | Mood flat but improving; no suicidal thoughts, elevated mood, or racing thoughts |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-01-20 to 2026-03-03 | completed | S |
| Sertraline 100 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-03-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-03 | Body height | 152 | cm | S |
| 2026-03-03 | Body weight | 50.2 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 76 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.6 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S |
Vital signs recorded on 2026-03-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Neatly dressed; more animated than at intake |
| Mental status | Alert; speech normal in rate; mood "better, but not myself"; affect mildly constricted and reactive; thought process linear; no suicidal ideation; insight and judgment good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Major depressive disorder, recurrent, moderate (moderately severe symptoms at intake), after a prolonged humanitarian deployment; synthetic modern diagnosis linked to her documented periods of depression and nervous prostration | active | confirmed | F33.1 | S — Synthetic modern diagnosis. Her periods of depression and nervous prostration are documented in her own words (D); calling them major depression is a retrospective interpretation (R), and no diagnosis was made in her lifetime. |
| Occupational burnout after eighteen months leading field medical relief in a war zone | active | confirmed | Z73.0 | S — Synthetic contributing factor echoing her documented exhaustion after wartime relief work; burnout is an occupational phenomenon, not a mental disorder. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 12, down 33 percent from 18: partial response; dose increased |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors unchanged; safety plan reviewed |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no side effects since the first week |
| Medication safety | Tolerability check two weeks after the dose increase | 2 weeks after each dose change | Due | Nurse telephone check booked for two weeks from today |
| Self-management | Psychotherapy, activity, sleep, work hours, and social contact | Every visit during active treatment | Completed today | Four CBT sessions; 25-hour week; sleep about five and a half hours; friends twice a week |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse telephone check in two weeks; depression review in six weeks. Next scheduled visit 2026-04-14: twelve-week depression treatment review. [S]